Journal
CLINICAL PHARMACOLOGY & THERAPEUTICS
Volume 92, Issue 1, Pages 112-117Publisher
WILEY
DOI: 10.1038/clpt.2012.57
Keywords
-
Categories
Funding
- National Institutes of Health [R01DK080007, U01HL069757, U19HL065962, U01HG006378, K23HL086556, R24 GM61374]
- Swedish Research Council [Medicine 523-2008-5568]
- Swedish Heart and Lung Foundation
- EU [HEALTH-F2-2009-223062]
- Clinical Research Support (ALF) at Uppsala University
- Sigrid Juselius Foundation (Helsinki, Finland)
- Helsinki University Central Hospital (Helsinki, Finland)
- European Research Council (Brussels, Belgium)
Ask authors/readers for more resources
Cholesterol reduction from statin therapy has been one of the greatest public health successes in modern medicine. Simvastatin is among the most commonly used prescription medications. A non-synonymous coding single-nucleotide polymorphism (SNP), rs4149056, in SLCO1B1 markedly increases systemic exposure to simvastatin and the risk of muscle toxicity. This guideline explores the relationship between rs4149056 (c.521T>C, p.V174A) and clinical outcome for all statins. The strength of the evidence is high for myopathy with simvastatin. We limit our recommendations accordingly.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
